patients (47%) in the cyclosporin A group and five (63%) in the azathioprine group showed fourfold rises in titer to at least one virus strain compared with 12 (100%) in the control group.
Cyclosporin A (CyA), a cyclic undecapeptide extracted from Cylindrocarpon lucidum and Trichoderma polysporum, was discovered in 1972 (1, 2) and has become an important antirejection agent that is now being used after graft surgery (7, 22) . It selectively inhibits one or more T cell functions sparing T suppressor cells (12) , and it inhibits production of interleukin 1 and 2 by macrophages and T lymphocytes (5) . CyA suppresses such cell-mediated immune responses as graft rejection, graft versus host disease, delayed hypersensitivity skin reactions, and experimental allergic encephalomyelitis in rodents (1, 2).
Thymus-dependent but not T-independent humoral immune responses are inhibited in mice (1, 2). However, by using human lymphocytes, Paavonen and Hary (18) demonstrated that Tdependent and T-independent antibody responses were inhibited by CyA in vitro.
This study was undertaken to determine the effect of CyA on response to influenza vaccine in renal transplant recipients, in the hope that this immunosuppressant might permit normal or near-normal antibody responses. Influenza vaccination is strongly recommended for persons with chronic renal disease (15) .
Three groups of individuals were studied. The first group (CyA group) consisted of 19 of subjects with preimmunization titers of <1:10 for each of the three antigens were also not significantly different among the three groups.
Immunization was well tolerated by all subjects. Only local soreness was reported. Serum creatinine levels of patients remained stable during the study period; they were 1.83 ± 0.12 mg/dl before and 1.92 ± 0.13 mg/dl after immunization for the CyA group and 1.32 ± 0.16 mg/dl before and 1.30 ± 0.12 mg/dl after for the Aza group. Normal levels in our laboratories are <1.4 mg/dl for males and <1.2 mg/dl for females. Poor renal function may impair antibody response in kidney recipients (15, 19) . Although most (22 of 27) patients in our series had mild elevations of serum creatinine level, no relationship to vaccine response could be observed. For instance, 8 of 15 patients (53%) with creatinine levels not more than 0.5 mg/dl above normal (mean of pre-and postimmunization determinations) responded to one or more antigens, and 6 of 12 (50%) with serum creatinine levels greater than 0.5 mg/dl above normal responded to at least one antigen.
The frequency of antibody responses is present in Table 1 This occurred in 14 instances. The results were therefore reanalyzed omitting these observations. The response rate and the magnitude of the response to B/Singapore in the CyA group and the magnitude of the response to B/Singapore in the Aza group were still significantly impaired. There were no subjects who had titers of >1:40 against A/Bangkok; hence, the significant reduction in the response to this antigen in the CyA and Aza groups was not affected.
The magnitude of HAI antibody rises and standard errors is shown in Fig. 1 . The preimmunization titers were similar in the three groups, with an overall mean of 1:9.9. In addition to a lower frequency of significant antibody responses, the CyA group also had significantly lower titer rises to each of three antigens compared with the control group (P < 0.01). The Aza group also showed lower antibody responses to A/Bangkok and B/Singapore than the control group (P < 0.05), but the rise in titer against A/Brazil was not statistically different from that of the controls.
We conclude that patients receiving CyA or Aza responded less well to influenza immunization than controls. The observed difference was probably not, as shown above, due to age (18) , prior immune status (13, 25) , or poor renal function (15, 19) (17) , typhoid vaccine (9), diphtheria toxoid (10) , and influenza vaccine (16) are not inhibited by cortisone. Butler (6) showed that volunteers treated with 96 mg of methylprednisolone for (8) reported that renal transplant recipients receiving Aza and prednisone were able to mount a normal antibody response to influenza vaccine. However, other studies (15, 19, 21, 23) described impaired antibody responses among such patients. In some, the impaired responses were related to poor renal function (15, 19) , but this relation could not be confirmed by others (3, 8, 21, 23) . Despite fair renal functions, our Aza patients had a significantly lower response rate and smaller antibody rises than controls. In this respect, they were similar to the CyA group. If there is a difference in the responses of our Aza and CyA groups, the number of patients in the Aza group was too small to show it.
CyA is capable of suppressing antibody formation in animals (1, 2) and in in vitro human peripheral blood lymphocytes (18) . Influenza hemagglutinin is probably a T-dependent antigen (23, 25) . The suppression of the antibody response against this antigen shown in this study is consistent with the theory that CyA inhibits Tdependent antibody response (2).
The primary antibody response was more easily inhibited by CyA in animal studies than the secondary response. Borel et al. (2) showed that the primary antibody response to sheep erythrocytes in mice was depressed by 20 mg of CyA per kg per day, but optimal suppression of the secondary response required 300 mg/kg per day. In our study, it is difficult to ascertain whether the primary antibody response was suppressed by CyA, because the number of subjects with no preimmunization titer (<1:10) was small, and this group would be expected to include subjects with levels of immunity not detected by HAI. Since serotypes H3N2 and HIN1 have been circulating since 1968 and 1978, respectively, it is possible that all subjects in our study had been previously exposed to these antigens. However, antibody responses in those who were seropositive (titer of -1:10) before immunization, certainly representing secondary antibody responses, were less in the CyA group than the control group (Table 1) 
